{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:19Z","timestamp":1777934659046,"version":"3.51.4"},"reference-count":49,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Several meta-analyses (MAs) of the efficacy and safety of daratumumab in refractory\/relapsed multiple myeloma (RRMM) exist. They include different types of populations, Daratumumab regimens, and outcomes. Moreover, there is a wide variation in methodological quality and risk of bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to conduct a systematic review of MAs to summarize the literature on the efficacy and safety profile of daratumumab use in RRMM, and also provide an assessment of the quality and risk of bias of the MAs if sufficient data is available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The literature databases Pubmed, Embase, Web of Science, and Cochrane were searched since inception. The quality of methodology was assessed by the AMSTAR-2 tool, and the risk of bias was assessed by the ROBIS tool.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight MAs were included in the SR. Most studies reported ORR and CR improvement by adding daratumumab to the chemotherapy regimen. Five MAs reported improvement in PFS in daratumumab-based regimens compared to non- daratumumab-based regimens. Only two MAs reported molecular response, favoring daratumumab. Dara was associated with adverse drug events (ADEs), including pneumonia and diarrhea. Conflicting evidence regarding hematological ADEs association with daratumumab exists. The overall quality of the studies is poor, but the MAs had a low risk of bias overall.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite including low-quality MAs, this SR provides a summary that simplifies clinicians\u2019 access to efficacy and safety outcomes of daratumumab in RRMM patients. Future studies are required to reduce the uncertainty and produce higher-quality Mas, particularly regarding daratumumab's safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241290452","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T05:39:01Z","timestamp":1732167541000},"page":"266-275","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of daratumumab for the treatment of refractory\/relapsed multiple myeloma. A systematic review of meta-analyses"],"prefix":"10.1177","volume":"31","author":[{"given":"Diala Alhaj","family":"Moustafa","sequence":"first","affiliation":[{"name":"College of Pharmacy, QU Health, Qatar University, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila","family":"Shafei","sequence":"additional","affiliation":[{"name":"College of Pharmacy, QU Health, Qatar University, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruba","family":"Sulaiman","sequence":"additional","affiliation":[{"name":"Biomedical Research Center, Qatar University, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A","family":"Yassin","sequence":"additional","affiliation":[{"name":"Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4162-8617","authenticated-orcid":false,"given":"Dina","family":"Abushanab","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef","family":"Algarabli","sequence":"additional","affiliation":[{"name":"Abbvie, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7791-954X","authenticated-orcid":false,"given":"Daoud","family":"Al-Badriyeh","sequence":"additional","affiliation":[{"name":"College of Pharmacy, QU Health, Qatar University, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_3_2_4_2","unstructured":"Surveillance Epidemiology and End Results (SEER) Program: National Cancer Institute (NCI). https:\/\/seer.cancer.gov\/."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2189"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013539"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40320-5_9"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.200"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0271-1"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405016"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2140284"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00128-5"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00579-9"},{"key":"e_1_3_2_19_2","first-page":"300060521103813","article-title":"Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"49","author":"Wang Y","year":"2021","unstructured":"Wang Y, Li Y, Chai Y. Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis. J Int Med Res 2021; 49: 3000605211038135.","journal-title":"J Int Med Res"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1987_21"},{"key":"e_1_3_2_21_2","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Br Med J 2017; 358: j4008.","journal-title":"Br Med J"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2015.06.005"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01440-x"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.797"},{"key":"e_1_3_2_25_2","article-title":"MM-082 Addition of daratumumab to drug regimens in the treatment of multiple myeloma: a systematic review and meta-analysis of randomized clinical trials","volume":"22","author":"Aiman W","year":"2022","unstructured":"Aiman W, Anwar A, Satti DI, et al. MM-082 Addition of daratumumab to drug regimens in the treatment of multiple myeloma: a systematic review and meta-analysis of randomized clinical trials. Clin Lymphoma Myeloma Leuk 2022; 22: S405.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"e_1_3_2_26_2","volume-title":"Risk of pneumonia and tolerability in patients with multiple myeloma treated with daratumumab: a systematic review and combined meta-analysis of six phase III randomised controlled trials","author":"Htut T","year":"2020","unstructured":"Htut T, Thein K, Win M, et al. Risk of pneumonia and tolerability in patients with multiple myeloma treated with daratumumab: a systematic review and combined meta-analysis of six phase III randomised controlled trials. Hoboken, NJ, USA: BRITISH JOURNAL OF HAEMATOLOGY, 2020."},{"key":"e_1_3_2_27_2","volume-title":"Efficacy of daratumumab combination regimen in patients with multiple myeloma: a combined analysis of six phase III randomised controlled trials","author":"Htut T","year":"2020","unstructured":"Htut T, Thein K, Win M, et al. Efficacy of daratumumab combination regimen in patients with multiple myeloma: a combined analysis of six phase III randomised controlled trials. Hoboken, NJ, USA: BRITISH JOURNAL OF HAEMATOLOGY, 2020."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110580"},{"key":"e_1_3_2_29_2","article-title":"Efficacy and safety of daratumumab in the treatment of relapsed\/refractory multiple myeloma: a meta-analysis of randomized controlled trials","volume":"102","author":"Huang ZY","year":"2023","unstructured":"Huang ZY, Jin XQ, Liang QL, et al. Efficacy and safety of daratumumab in the treatment of relapsed\/refractory multiple myeloma: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2023; 102: e35319.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-15"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00328-2"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_2_35_2","first-page":"4017","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva B","year":"2008","unstructured":"Paiva B, Vidriales M-B, Cerver\u00f3 J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood, J Am Soc Hematol 2008; 112: 4017\u20134023.","journal-title":"Blood, J Am Soc Hematol"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.1967"},{"key":"e_1_3_2_37_2","first-page":"3095","article-title":"Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation","volume":"100","author":"Rawstron AC","year":"2002","unstructured":"Rawstron AC, Davies FE, DasGupta R, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood, J Ame Soc Hematol 2002; 100: 3095\u20133100.","journal-title":"Blood, J Ame Soc Hematol"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235886"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03353-5"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4338"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103211"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123145"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.817762"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e20005"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.08.019"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.02.017"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2010.10.016"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.6971"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/10669817.2020.1839728"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-020-00999-9"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241290452","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241290452","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241290452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:30:27Z","timestamp":1777689027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241290452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/10781552241290452"],"URL":"https:\/\/doi.org\/10.1177\/10781552241290452","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,21]]}}}